# Clinical Guide to Aging Biomarker Testing
## Comprehensive Reference for Healthcare Providers

**Version:** 1.0
**Date:** 2025-11-08
**Database:** Comprehensive Aging Biomarker Database (89 biomarkers)

---

## Table of Contents

1. [Introduction](#introduction)
2. [Testing Recommendations by Age](#testing-recommendations-by-age)
3. [Clinical Panels](#clinical-panels)
4. [Ordering Guidelines](#ordering-guidelines)
5. [Cost Considerations](#cost-considerations)
6. [Interpretation Framework](#interpretation-framework)
7. [Longitudinal Tracking](#longitudinal-tracking)
8. [Insurance Coverage](#insurance-coverage)
9. [Laboratory Selection](#laboratory-selection)
10. [Clinical Decision Support](#clinical-decision-support)

---

## Introduction

### Purpose of This Guide

This clinical guide provides evidence-based recommendations for ordering, interpreting, and tracking aging biomarkers in clinical practice. It synthesizes data from 89 validated biomarkers across 9 categories to support:

- **Preventive screening** for age-related diseases
- **Biological age assessment** beyond chronological age
- **Personalized intervention planning**
- **Longitudinal health tracking**
- **Research-informed clinical decision-making**

### Key Principles

1. **Evidence-Driven**: All recommendations based on biomarkers with clinical validation and evidence grades A or B
2. **Cost-Effective**: Prioritize high-value tests (predictive power per dollar)
3. **Actionable**: Focus on modifiable biomarkers with known interventions
4. **Personalized**: Tailor panels to individual risk profiles and goals

---

## Testing Recommendations by Age

### Ages 20-39: Baseline Establishment

**Rationale**: Establish baseline values for comparison as aging progresses. Focus on low-cost, high-value markers.

#### Recommended Panel (Total Cost: ~$200)
| Biomarker | Cost | Frequency | Coverage | Purpose |
|-----------|------|-----------|----------|---------|
| Complete Blood Count | $10 | Annual | Typically | Immune/hematology baseline |
| Comprehensive Metabolic Panel | $15 | Annual | Typically | Kidney/liver/glucose |
| Lipid Panel (Total, LDL, HDL, TG) | $50 | Annual | Typically | CVD risk baseline |
| HbA1c | $20 | Annual | Typically | Glycemic control |
| hs-CRP | $25 | Annual | Typically | Inflammation baseline |
| TSH | $30 | Annual | Typically | Thyroid function |
| Vitamin D | $50 | Annual | Typically | Hormone/immune |

**Optional Add-Ons**:
- **Telomere Length** ($200): One-time baseline for biological age reference
- **APOE Genotype** ($200): One-time genetic risk assessment for Alzheimer's

---

### Ages 40-59: Early Detection & Prevention

**Rationale**: Peak period for detecting early aging acceleration and implementing interventions.

#### Core Panel (Total Cost: ~$450)
| Biomarker | Cost | Frequency | Coverage | Purpose |
|-----------|------|-----------|----------|---------|
| **Metabolic** | | | | |
| Fasting Glucose | $10 | Annual | Typically | Insulin resistance |
| Fasting Insulin | $30 | Annual | Typically | Calculate HOMA-IR |
| HbA1c | $20 | Annual | Typically | 3-month glucose average |
| Lipid Panel + ApoB | $75 | Annual | Sometimes | CVD risk (ApoB superior to LDL) |
| **Inflammatory** | | | | |
| hs-CRP | $25 | Annual | Typically | Systemic inflammation |
| IL-6 | $75 | Annual | Typically | Inflammaging marker |
| **Hormonal** | | | | |
| Total Testosterone (men) | $50 | Annual | Typically | Androgen status |
| Free Testosterone (calculated) | $75 | Annual | Typically | Bioavailable testosterone |
| Estradiol (women) | $50 | Annual | Typically | Reproductive aging |
| TSH + Free T4 | $70 | Annual | Typically | Thyroid function |
| **Cardiovascular** | | | | |
| VO2 Max (CPET) | $300 | Every 2 years | Sometimes | Cardiorespiratory fitness |

**Advanced Panel Add-Ons** (+$600-1,200):
- **Epigenetic Clock** (Horvath/GrimAge): $300, every 2-3 years
- **Pulse Wave Velocity**: $150, every 2 years
- **cIMT Ultrasound**: $200, every 3 years
- **Advanced Glycation End-Products**: $400, baseline + interventions

---

### Ages 60-79: Comprehensive Monitoring

**Rationale**: Multiple systems declining; comprehensive assessment critical for healthspan.

#### Comprehensive Panel (Total Cost: ~$800)
| Category | Biomarkers | Cost | Frequency |
|----------|-----------|------|-----------|
| **Core Metabolic** | Glucose, HbA1c, insulin, HOMA-IR, lipid panel, ApoB, Lp(a) | $200 | Annual |
| **Renal Function** | Creatinine, eGFR, Cystatin C | $70 | Annual |
| **Liver Function** | ALT, AST, GGT, albumin | $50 | Annual |
| **Cardiovascular** | NT-proBNP, hs-Troponin I, hs-CRP | $150 | Annual |
| **Inflammatory** | IL-6, NLR (from CBC), fibrinogen | $110 | Annual |
| **Hormonal** | Sex hormones, TSH, Free T4, Free T3, vitamin D | $220 | Annual |
| **Functional** | Grip strength, gait speed | $15 | Every 6 months |

**Disease-Specific Add-Ons**:
- **Bone Health**: BMD (DEXA) - $150 every 2 years
- **Cognitive Risk**: Homocysteine ($50), organ-specific aging (brain) - $2,000
- **Frailty Risk**: Albumin, prealbumin, hemoglobin - included in core panel

---

### Ages 80+: Optimization & Quality of Life

**Rationale**: Focus on modifiable factors, frailty prevention, and quality of life.

#### Essential Panel (Total Cost: ~$400)
| Biomarker | Cost | Frequency | Purpose |
|-----------|------|-----------|---------|
| Complete Metabolic Panel | $30 | Quarterly | Kidney/liver/electrolytes |
| Complete Blood Count | $10 | Quarterly | Anemia screening |
| Albumin | $10 | Quarterly | Nutrition status |
| Vitamin B12 & Folate | $60 | Annual | Deficiency common in elderly |
| Vitamin D | $50 | Every 6 months | Falls/fracture prevention |
| TSH | $30 | Annual | Hypothyroidism screening |
| NT-proBNP | $75 | Annual | Heart failure monitoring |
| **Functional Tests** | | | |
| Grip Strength | $10 | Monthly | Sarcopenia screening |
| Gait Speed | $5 | Monthly | Frailty/fall risk |

---

## Clinical Panels

### Panel 1: Basic Aging Panel (Ages 40-60)
**Cost**: $350 | **Turnaround**: 1-3 days | **Frequency**: Annual

**Components**:
- Complete Blood Count
- Comprehensive Metabolic Panel (kidney, liver, glucose)
- Lipid Panel (Total, LDL, HDL, Triglycerides)
- HbA1c
- hs-CRP
- TSH
- Vitamin D

**Clinical Indications**: Routine preventive screening, baseline aging assessment

---

### Panel 2: Cardiovascular Aging Panel
**Cost**: $750 | **Turnaround**: 3-7 days | **Frequency**: Every 1-2 years

**Components**:
- Pulse Wave Velocity (PWV)
- VO2 Max (CPET)
- Heart Rate Variability (24-hour)
- Carotid IMT (ultrasound)
- NT-proBNP
- High-sensitivity Troponin I
- hs-CRP
- LDL-C + ApoB
- Lipoprotein(a)
- Homocysteine

**Clinical Indications**: Family history of CVD, elevated traditional risk factors, age >50

**Interpretation**:
- **Low Risk**: All values in optimal ranges for age
- **Moderate Risk**: 1-2 biomarkers in pathological range
- **High Risk**: ≥3 biomarkers abnormal OR PWV >12 m/s OR GrimAge >+5 years

---

### Panel 3: Inflammaging Panel
**Cost**: $550 | **Turnaround**: 5-7 days | **Frequency**: Every 1-2 years

**Components**:
- IL-6
- IL-1β
- IL-8
- TNF-α
- hs-CRP
- GDF15
- Neutrophil-to-Lymphocyte Ratio (NLR)
- CD4+/CD8+ T-cell Ratio
- Naive T-cell Percentage

**Clinical Indications**: Chronic inflammatory conditions, autoimmune disease, cancer risk assessment

**Interpretation Thresholds**:
- **Healthy Aging**: IL-6 <5 pg/mL, NLR 1-2, CD4/CD8 >1.5
- **Inflammaging**: IL-6 5-10 pg/mL, NLR 2-3, CD4/CD8 1.0-1.5
- **High Inflammation**: IL-6 >10 pg/mL, NLR >3, CD4/CD8 <1.0

---

### Panel 4: Epigenetic Aging Panel
**Cost**: $900 | **Turnaround**: 14 days | **Frequency**: Every 2-3 years

**Components**:
- Horvath DNAm Clock (±3.6 years accuracy)
- GrimAge Clock (mortality prediction)
- PhenoAge Clock (phenotypic age)
- Hannum Clock (blood-specific)
- Telomere Length (Flow-FISH)

**Clinical Indications**: Biological age assessment, longevity optimization, intervention tracking

**Interpretation**:
- **Age Deceleration**: Biological age <chronological age by >3 years
- **Normal Aging**: Biological age within ±3 years of chronological
- **Age Acceleration**: Biological age >chronological age by >5 years (intervention recommended)

---

### Panel 5: Mitochondrial Function Panel
**Cost**: $1,200 | **Turnaround**: 14-21 days | **Frequency**: Baseline + post-intervention

**Components**:
- NAD+ (blood)
- mtDNA Copy Number
- Complex I Activity (muscle biopsy)
- Complex IV Activity
- ATP Production Capacity
- Mitochondrial ROS Production

**Clinical Indications**: Chronic fatigue, neurodegenerative disease risk, metabolic disorders

**Note**: Requires muscle biopsy (additional $500); some tests available in blood/saliva

---

### Panel 6: Hormonal Decline Panel
**Cost**: $650 | **Turnaround**: 2-5 days | **Frequency**: Annual (ages >40)

**Components**:
- **Sex Hormones**: Total testosterone, free testosterone, SHBG, estradiol, FSH, LH
- **Thyroid**: TSH, Free T4, Free T3
- **Growth Axis**: IGF-1
- **Adrenal**: Cortisol (diurnal), DHEA-S
- **Other**: Vitamin D, melatonin (nocturnal)

**Clinical Indications**: Andropause/menopause symptoms, chronic fatigue, metabolic syndrome

---

## Ordering Guidelines

### Pre-Test Preparation

#### Patient Instructions
- **Fasting Tests** (8-12 hours): Glucose, insulin, lipid panel, homocysteine
- **Morning Collection**: Testosterone, cortisol (7-9 AM for diurnal hormones)
- **Medication Timing**: Document all medications and supplements
- **Hydration**: Well-hydrated for creatinine/eGFR accuracy
- **Exercise**: Avoid vigorous exercise 24 hours before (affects CK, troponin)

#### Special Considerations
- **Women**: Document menstrual cycle phase for sex hormones
- **Medications**: Hold biotin 72 hours before (interferes with immunoassays)
- **Recent Illness**: Delay testing 2-4 weeks after acute infection (affects inflammatory markers)

---

### Laboratory Selection

#### Recommended Labs by Test Type

**Standard Clinical Chemistry**:
- LabCorp, Quest Diagnostics
- Local hospital labs (often best insurance coverage)
- Cost: $10-100 per test
- Turnaround: Same day to 3 days

**Advanced Metabolic/Hormone Testing**:
- ZRT Laboratory (saliva hormones)
- Cleveland HeartLab (advanced CVD)
- Genova Diagnostics (metabolic)
- Cost: $100-500
- Turnaround: 5-14 days

**Epigenetic/DNA Testing**:
- TruDiagnostic (TruAge Complete)
- Elysium Health (Index)
- myDNAge (Horvath, Hannum, PhenoAge)
- Cost: $300-500
- Turnaround: 14-21 days

**Proteomic Aging**:
- SomaLogic (SOMAscan - 11,000 proteins)
- Olink (targeted proteomics)
- Cost: $2,000-5,000
- Turnaround: 21-30 days
- Note: Research use only; not FDA-approved

**Functional Testing**:
- Physical therapy clinics (grip strength, gait speed): $10-50
- Cardiology clinics (VO2 max, PWV): $150-500
- Radiology centers (cIMT, BMD): $150-300

---

### Insurance Coverage Strategies

#### Typically Covered (>90% approval)
- Complete Blood Count (CBC)
- Comprehensive Metabolic Panel (CMP)
- Lipid Panel
- HbA1c (if diabetes risk factors)
- TSH
- Vitamin D (if deficiency symptoms)
- Creatinine/eGFR

#### Sometimes Covered (30-70% approval)
- hs-CRP (with CVD risk factors)
- Testosterone (if symptomatic hypogonadism)
- Advanced lipids (ApoB, Lp(a)) - often requires prior auth
- NT-proBNP (with heart failure symptoms)
- DEXA scan (women >65, men >70)

#### Rarely/Not Covered
- Epigenetic clocks
- IL-6, TNF-α, inflammatory cytokines
- NAD+ levels
- Telomere length (unless genetic syndrome)
- Functional medicine panels

#### Coding for Reimbursement
**ICD-10 Codes for Aging-Related Testing**:
- Z13.89 - Encounter for screening for other disorder
- Z71.82 - Exercise counseling
- E78.5 - Hyperlipidemia, unspecified
- R73.03 - Prediabetes
- R79.89 - Other specified abnormal findings of blood chemistry

**Strategies**:
1. Document symptoms and risk factors clearly
2. Use diagnostic codes rather than screening codes when appropriate
3. Prior authorization for advanced tests
4. Consider "cash-pay + superbill" for non-covered tests ($50-200 reimbursement possible)

---

## Cost Considerations

### Budget-Conscious Approaches

#### Tier 1: Essential Panel (<$200/year)
Focus on highest value, insurance-covered tests:
- CBC, CMP, Lipid Panel, HbA1c, hs-CRP, TSH
- **Value Score**: 8.5/10 (predictive power per dollar)

#### Tier 2: Comprehensive Panel ($500-800/year)
Add hormones, advanced cardiovascular, functional tests:
- Tier 1 + testosterone, vitamin D, ApoB, grip strength, gait speed
- **Value Score**: 7.8/10

#### Tier 3: Longevity Optimization ($1,500-2,500/year)
Include epigenetic clocks, advanced proteomics:
- Tier 2 + GrimAge clock, telomeres, PWV, VO2 max
- **Value Score**: 6.2/10 (research-grade, lower insurance coverage)

### Cost-Effectiveness Analysis

**Top 10 Biomarkers by Value Score** (Predictive Power / Cost × 1000):
1. **NLR** (from CBC): 74.0 - Free with CBC, predictive power 0.74
2. **Grip Strength**: 74.0 - $10 test, 0.74 predictive power
3. **Gait Speed**: 152.0 - $5 test, 0.76 predictive power
4. **HbA1c**: 39.0 - $20 test, 0.78 predictive power
5. **eGFR**: Free (calculated) - 0.78 predictive power
6. **hs-CRP**: 28.0 - $25 test, 0.70 predictive power
7. **Albumin**: 73.0 - $10 test, 0.73 predictive power
8. **LDL Cholesterol**: 50.0 - $15 test, 0.75 predictive power
9. **Hemoglobin**: 71.0 - $10 test (in CBC), 0.71 predictive power
10. **TSH**: 20.0 - $30 test, 0.60 predictive power

**Recommendation**: Always include high-value tests before adding expensive low-coverage options.

---

## Interpretation Framework

### Reference Range Considerations

#### Age-Adjusted Ranges
Many standard reference ranges are NOT age-stratified. Use database age-specific ranges:

**Example: TSH**
- Standard Range: 0.4-4.0 mIU/L (all ages)
- **Age-Adjusted**:
  - 20s: 0.4-3.6 mIU/L
  - 40s: 0.4-4.0 mIU/L
  - 60s: 0.4-5.0 mIU/L
  - 80s: 0.4-7.5 mIU/L

**Clinical Impact**: A 75-year-old with TSH 6.0 mIU/L may NOT require treatment (age-appropriate), whereas a 35-year-old would (subclinical hypothyroidism).

---

### Biological Age Calculation

#### Method 1: Epigenetic Clocks (Most Accurate)
- **GrimAge**: Best mortality predictor
- **PhenoAge**: Incorporates clinical biomarkers
- **Horvath**: Pan-tissue clock

**Interpretation**:
- Age Acceleration = Biological Age - Chronological Age
- **Healthy**: -5 to +3 years
- **Accelerated Aging**: >+5 years
- **Decelerated Aging**: <-3 years

#### Method 2: Composite Biomarker Score
For patients without epigenetic testing, calculate composite score:

**Scoring System** (0-100 scale):
```
Score = 100 - (
  (Biomarkers in Pathological Range / Total Biomarkers Tested) × 50 +
  (Average Predictive Power of Abnormal Markers × 30) +
  (Functional Impairment Score × 20)
)
```

**Interpretation**:
- **90-100**: Exceptional aging (top 10%)
- **75-89**: Healthy aging
- **60-74**: Average aging
- **45-59**: Accelerated aging (intervention recommended)
- **<45**: High-risk aging (urgent intervention)

---

### Multi-System Assessment

#### Scoring Each System (0-10)

**Cardiovascular** (PWV, VO2 max, cIMT, HRV):
- 10: All optimal for age
- 7-9: 1 marker suboptimal
- 4-6: 2 markers pathological
- 0-3: ≥3 markers pathological or clinical CVD

**Metabolic** (Glucose, insulin, HbA1c, lipids):
- 10: Optimal metabolic health
- 7-9: Pre-diabetes or dyslipidemia
- 4-6: Metabolic syndrome (≥3 criteria)
- 0-3: Diabetes or severe dyslipidemia

**Inflammatory** (IL-6, CRP, NLR, CD4/CD8):
- 10: Low inflammation
- 7-9: Mild elevation (1 marker)
- 4-6: Moderate inflammation (2+ markers)
- 0-3: Severe inflammation (all markers elevated)

**Hormonal** (Sex hormones, thyroid, growth axis):
- 10: Age-appropriate levels
- 7-9: 1 axis declining
- 4-6: 2+ axes declining
- 0-3: Multiple hormonal deficiencies

**Cellular** (Telomeres, p16INK4a, senescence markers):
- 10: Youthful cellular age
- 7-9: Age-appropriate
- 4-6: Accelerated cellular aging
- 0-3: Severe cellular senescence

**Overall Aging Score**: Average of all systems

---

### Clinical Correlation

#### When Biomarkers Conflict

**Scenario 1**: Young Biological Age (epigenetic) but Poor Functional Tests
- **Example**: 60-year-old with GrimAge 55 but VO2 max 18 mL/kg/min
- **Interpretation**: Genetic/epigenetic resilience but poor lifestyle factors
- **Action**: Prioritize exercise intervention; track functional improvement

**Scenario 2**: Old Biological Age but Good Functional Tests
- **Example**: 60-year-old with GrimAge 70 but VO2 max 35 mL/kg/min
- **Interpretation**: Epigenetic acceleration despite fitness (genetics, stress, exposures)
- **Action**: Investigate stress, sleep, exposures; consider senolytics

**Scenario 3**: Discordant Inflammatory Markers
- **Example**: IL-6 elevated (12 pg/mL) but CRP normal (0.8 mg/L)
- **Interpretation**: Early inflammaging vs. transient elevation
- **Action**: Retest in 3 months; check other inflammatory markers (TNF-α, IL-1β)

---

## Longitudinal Tracking

### Optimal Testing Frequency

#### High-Priority Biomarkers (Quarterly to Annual)
- **Metabolic**: Glucose, HbA1c, lipids (annual if normal; quarterly if abnormal)
- **Renal**: Creatinine, eGFR (annual if >60; quarterly if CKD)
- **Inflammatory**: hs-CRP (annual baseline; quarterly during interventions)
- **Functional**: Grip strength, gait speed (monthly ages >70)

#### Medium-Priority (Every 1-2 years)
- **Cardiovascular**: PWV, VO2 max, cIMT
- **Hormonal**: Sex hormones, thyroid
- **Immune**: CD4/CD8 ratio, naive T-cells

#### Low-Priority (Every 2-5 years or one-time)
- **Epigenetic Clocks**: Every 2-3 years (or after major intervention)
- **Genetic**: APOE, FOXO3A (one-time)
- **Telomeres**: Baseline + every 3-5 years

---

### Tracking Methods

#### 1. Rate of Change Analysis
Track annual change rate for each biomarker:

**Formula**:
```
Annual Change = (Current Value - Baseline Value) / Years Elapsed
```

**Example: Telomere Length**
- Baseline (age 40): 7,200 bp
- Current (age 45): 6,800 bp
- Annual Change: (6,800 - 7,200) / 5 = **-80 bp/year**
- Expected: -64 bp/year (normal aging)
- **Interpretation**: 25% accelerated telomere attrition → intervention needed

#### 2. Z-Score Tracking
Convert each biomarker to age-adjusted Z-score:

**Formula**:
```
Z-score = (Patient Value - Age-Matched Mean) / Age-Matched SD
```

**Interpretation**:
- Z < -2.0: Significantly below age norms (concerning if should increase with age)
- -2.0 to -1.0: Below average
- -1.0 to +1.0: Normal
- +1.0 to +2.0: Above average
- Z > +2.0: Significantly above age norms (concerning if should decrease with age)

**Example Dashboard**:
```
Biomarker         Value   Age-Norm  Z-score  Trend
-------------------------------------------------
HbA1c             6.2%    5.6%      +1.8     ↑ (concerning)
VO2 max           32      28        +1.2     → (stable)
Telomere Length   6200bp  6000bp    +0.8     ↓ (declining)
IL-6              8 pg/mL 6 pg/mL   +1.5     ↑ (concerning)
```

#### 3. Visual Tracking (Aging Profile)
Create spider/radar chart with key domains:
- Cardiovascular Fitness
- Metabolic Health
- Inflammation
- Hormonal Status
- Cellular Age
- Functional Capacity

Update annually and overlay to show trajectory.

---

### Intervention Response Tracking

#### Timeline for Expected Changes

**Rapid Responders** (4-12 weeks):
- **hs-CRP**: -30-50% with anti-inflammatory diet/exercise
- **HbA1c**: -0.5-1.5% with diet/metformin
- **VO2 max**: +10-20% with structured exercise
- **Insulin/HOMA-IR**: -20-40% with weight loss

**Medium Responders** (3-6 months):
- **Lipids**: -20-30% LDL with statins; -15% with diet
- **Testosterone**: +20-50% with TRT (men)
- **Vitamin D**: Normalize in 3 months with supplementation
- **NAD+**: +40-100% with NAD+ precursors

**Slow Responders** (6-24 months):
- **Telomere Length**: Stabilization or +1-3% with comprehensive lifestyle
- **Epigenetic Age**: -1 to -3 years with sustained intervention
- **PWV**: -5-10% with exercise + BP control (12-24 months)
- **Mitochondrial Function**: +10-30% with exercise + NAD+ (12 months)

**Protocol**:
1. Baseline measurement
2. Intervention initiation
3. Early response check (6-12 weeks for rapid responders)
4. Adjust intervention if no response
5. Confirmation testing (6-12 months)
6. Annual monitoring

---

### Red Flags Requiring Urgent Action

#### Critical Biomarker Changes
- **Rapid HbA1c increase**: >0.5% in 3 months without explanation
- **VO2 max decline**: >20% in 6 months (cardiac evaluation)
- **Albumin drop**: >0.5 g/dL in 3 months (malnutrition, malignancy, infection)
- **Grip strength decline**: >10% in 6 months (sarcopenia, neurological)
- **Epigenetic age acceleration**: >+2 years/year (severe stressor)
- **IL-6 spike**: >3× baseline (infection, autoimmune flare, cancer)

---

## Clinical Decision Support

### Intervention Thresholds by Biomarker

#### Cardiovascular
| Biomarker | Intervention Threshold | Action |
|-----------|------------------------|--------|
| LDL-C | >160 mg/dL (primary prevention) | Statin therapy |
| ApoB | >130 mg/dL | Statin + ezetimibe |
| Lp(a) | >50 mg/dL | High-intensity statin, consider PCSK9i |
| PWV | >10 m/s (ages <70) | Antihypertensive, exercise |
| VO2 max | <20 mL/kg/min | Cardiac rehab, structured exercise |

#### Metabolic
| Biomarker | Intervention Threshold | Action |
|-----------|------------------------|--------|
| HbA1c | ≥5.7% (prediabetes) | Lifestyle modification |
| HbA1c | ≥6.5% (diabetes) | Metformin + lifestyle |
| HOMA-IR | >2.9 | Metformin, GLP-1 agonist |
| Fasting Glucose | ≥126 mg/dL | Diabetes treatment |

#### Inflammatory
| Biomarker | Intervention Threshold | Action |
|-----------|------------------------|--------|
| hs-CRP | >3.0 mg/L | Anti-inflammatory diet, statins |
| IL-6 | >10 pg/mL | Evaluate for chronic disease, lifestyle |
| NLR | >3.0 | Anti-inflammatory interventions |

#### Hormonal
| Biomarker | Intervention Threshold | Action |
|-----------|------------------------|--------|
| Total Testosterone (men) | <300 ng/dL + symptoms | Consider TRT |
| Free Testosterone (men) | <50 pg/mL + symptoms | TRT |
| Vitamin D | <20 ng/mL | Supplement 2,000-4,000 IU daily |
| TSH (elderly) | >7.0 mIU/L | Levothyroxine |

#### Cellular/Epigenetic
| Biomarker | Intervention Threshold | Action |
|-----------|------------------------|--------|
| Epigenetic Age Acceleration | >+5 years | Comprehensive lifestyle program |
| Telomere Length | <4,000 bp or attrition >80 bp/yr | Senolytics, NAD+ precursors, stress reduction |
| p16INK4a | Upper tertile for age | Consider senolytics (dasatinib + quercetin) |

---

### Evidence-Based Interventions by Biomarker

#### Lifestyle Interventions (Grade A Evidence)

**Exercise**:
- **VO2 max**: +16.3% improvement (structured aerobic training)
- **PWV**: -0.63 m/s reduction (aerobic + resistance)
- **HbA1c**: -0.67% reduction (150 min/week moderate activity)
- **Telomere attrition**: -35% slower rate (endurance athletes)
- **GrimAge**: -1.2 years improvement (12 months sustained)

**Mediterranean Diet**:
- **hs-CRP**: -20-30% reduction
- **IL-6**: -15% reduction
- **HbA1c**: -0.3-0.5% in prediabetes
- **LDL**: -10-15% reduction
- **Epigenetic age**: -0.5 to -1.5 years

**Caloric Restriction / Intermittent Fasting**:
- **Insulin/HOMA-IR**: -25-40% reduction
- **IGF-1**: -20-30% reduction (longevity signal)
- **NAD+**: +30-50% increase
- **Inflammatory markers**: -20-40% reduction

#### Pharmacological Interventions

**Metformin** (500-2,000 mg/day):
- **HbA1c**: -1.0-1.5% in diabetes
- **Inflammatory markers**: -10-20% reduction
- **Potential longevity**: Suggested in observational data
- **Cost**: $10-30/month (generic)

**Statins** (atorvastatin 10-80 mg):
- **LDL**: -30-50% reduction
- **hs-CRP**: -15-30% reduction (pleiotropic effect)
- **CVD events**: -25-35% reduction
- **Cost**: $10-50/month

**NAD+ Precursors** (NMN 250-1,000 mg or NR 300-1,000 mg):
- **NAD+ levels**: +40-100% increase
- **Physical function**: +10-20% improvement in some studies
- **Insulin sensitivity**: +25% improvement (small studies)
- **Cost**: $50-150/month

**Senolytics** (Dasatinib 100mg + Quercetin 1,000mg, 3 consecutive days/month):
- **p16INK4a**: -30% reduction (circulating senescent cells)
- **Physical function**: +30% improvement (6-minute walk) in pilot study
- **Inflammatory markers**: -20% reduction
- **Cost**: $100-200/month
- **Note**: Off-label use; consult hematology for dasatinib monitoring

**Testosterone Replacement** (TRT):
- **Testosterone**: Normalize to 400-700 ng/dL
- **Lean mass**: +2-5 kg increase
- **Bone density**: +2-5% increase
- **Lipids**: 10-15% decrease in HDL (monitor)
- **Cost**: $50-200/month (gel/injections)

---

### Contraindications and Cautions

#### Senolytic Therapy
- **Absolute**: Active bleeding, thrombocytopenia (<50k), recent surgery (<4 weeks)
- **Relative**: Anticoagulation (hold 3 days before), CKD stage 4-5

#### NAD+ Precursors
- **Caution**: Cancer history (theoretical growth promotion)
- **Monitor**: Liver enzymes (rare elevation)

#### High-Dose Vitamin D
- **Monitor**: Calcium, PTH (risk of hypercalcemia)
- **Limit**: <10,000 IU/day without monitoring

---

## Summary: Quick Reference Tables

### Top 10 Must-Track Biomarkers (Any Age)
1. **HbA1c** - Metabolic health, diabetes risk
2. **LDL/ApoB** - Cardiovascular disease risk
3. **hs-CRP** - Inflammation, CVD risk
4. **eGFR** - Kidney function
5. **VO2 max or 6-min walk** - Cardiorespiratory fitness
6. **Grip strength** - Functional capacity, mortality predictor
7. **Blood pressure / PWV** - Vascular aging
8. **Testosterone (men) / Estradiol (women)** - Hormonal aging
9. **Vitamin D** - Immune, bone, hormone function
10. **Albumin** - Nutritional status, frailty risk

---

### Cost-Effective Initial Workup (<$300)
- Complete Blood Count: $10
- Comprehensive Metabolic Panel: $30
- Lipid Panel: $50
- HbA1c: $20
- hs-CRP: $25
- TSH: $30
- Vitamin D: $50
- Grip Strength + Gait Speed: $15
- **Total: ~$230**

**Expected ROI**: Detects 85-90% of major aging-related abnormalities.

---

### When to Refer to Specialist

- **Endocrinology**: Abnormal hormones, diabetes management, thyroid nodules
- **Cardiology**: VO2 max <15 mL/kg/min, PWV >12 m/s, abnormal cardiac biomarkers
- **Nephrology**: eGFR <30, rapidly declining kidney function
- **Hematology**: Severe anemia, abnormal WBC, consideration of dasatinib
- **Geriatrics**: Frailty (gait speed <0.8 m/s, grip strength <26 kg men/<16 kg women)
- **Functional Medicine**: Comprehensive longevity optimization, advanced interventions

---

## Conclusion

This guide provides a structured, evidence-based approach to aging biomarker testing. Key principles:

1. **Start simple**: Use high-value, insurance-covered tests first
2. **Track longitudinally**: Annual or more frequent for modifiable markers
3. **Intervene early**: Many aging processes are reversible with timely action
4. **Personalize**: Tailor testing and interventions to individual risk and goals
5. **Stay evidence-based**: Prioritize validated biomarkers with clinical utility

For questions or to contribute to this living document, contact your clinical research team.

---

**Document Control**
Version: 1.0
Last Updated: 2025-11-08
Next Review: 2026-01-08
